Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 7/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455670 | 1.00 | — | — | |
| Dodecyl Methyl Sulfoxide SCHEMBL313076 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL29144 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL7864589 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL221373 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL5074212 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL224939 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL8587009 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL160437 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS | |
| SCHEMBL5294900 | 1.00 | TSHR (0.47) | TSHRTHRBCES2CES1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1541 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124499-B2 | Pharmaceutical composition derived from Tecoma plant and a method for treating cancer | NATIONAL GUARD HEALTH AFFAIRS (SA) | 2021-09-21 | — | — | US | claimed |
| US-20200247786-A1 | PHARMACEUTICAL COMPOSITION DERIVED FROM TECOMA PLANT AND A METHOD FOR TREATING CANCER | NATIONAL GUARD HEALTH AFFAIRS (SA) | 2020-08-06 | — | — | US | claimed |
| US-10292972-B1 | Pharmaceutical composition for treating cancer and a method thereof | KING ABDULAZIZ UNIVERSITY (SA) | 2019-05-21 | — | — | US | claimed |
| US-20190125732-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND A METHOD THEREOF | KING ABDULAZIZ UNIVERSITY (SA) | 2019-05-02 | — | — | US | claimed |
| US-9320734-B2 | Small molecule inhibitors of the pleckstrin homology domain and methods for using same | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-04-26 | — | — | US | claimed |
| US-20150126563-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-05-07 | — | — | US | claimed |
| US-8852648-B2 | Delivery of biologically-active agents using volatile, hydrophobic solvents | ROCHAL INDUSTRIES, LLP (US) | 2014-10-07 | — | — | US | claimed |
| US-20140127320-A1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL INDUSTRIES, LLP (US) | 2014-05-08 | — | — | US | claimed |
| US-20130071450-A1 | GELS FOR TRANSDERMAL DELIVERY | COVIDIEN LP (US) | 2013-03-21 | — | — | US | claimed |
| US-20120189670-A1 | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS INCLUDING INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PHUSIS THERAPEUTICS INC. | 2012-07-26 | — | — | US | claimed |
| US-20110230816-A1 | Gels for Transdermal Delivery | TYCO HEALTHCARE GROUP LP (US) | 2011-09-22 | — | — | US | claimed |
| WO-2011032169-A2 | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS INCLUDING INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PHUSIS THERAPEUTICS INC. (US) | 2011-03-17 | — | — | WO | claimed |
| CN-101605458-A | High dose, long acting ectoparasiticides for extended control | WYETH CORP (US) | 2009-12-16 | — | — | CN | claimed |
| EP-2120583-A2 | HIGH-DOSE, LONG-ACTING ECTOPARASITICIDE FOR EXTENDED CONTROL | Wyeth (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2008098168-A2 | HIGH-DOSE, LONG-ACTING ECTOPARASITICIDE FOR EXTENDED CONTROL | WYETH (US) | 2008-08-14 | — | — | WO | claimed |
| US-20080112993-A1 | High-dose, long-lasting ectoparasiticide for extended control | WYETH (US) | 2008-05-15 | — | — | US | claimed |
| US-20060003948-A1 | Compositions that include a triterpene and a carrier | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2006-01-05 | — | — | US | claimed |
| WO-2005077377-A1 | COMPOSITIONS THAT INCLUDE A TRITERPENE AND A CARRIER | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2005-08-25 | — | — | WO | claimed |
| US-20050014730-A1 | Anti-fungal formulation of triterpene and essential oil | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2005-01-20 | — | — | US | claimed |
| WO-2004089357-A2 | ANTI-FUNGAL FORMULATION OF TRITERPENE AND ESSENTIAL OIL | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2004-10-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126563-A1 | SMALL MOLECULE INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PLEKHG3, PLEKHA1, PLEC | TSHR 4193/4885THRB 3355/4885CES2 3667/4885 |
| US-20080112993-A1 | High-dose, long-lasting ectoparasiticide for extended control | VEGFA, ENPP3, ESYT2 | TSHR 4287/4885THRB 4406/4885CES2 1183/4885 |
| US-10292972-B1 | Pharmaceutical composition for treating cancer and a method thereof | SYMPK, ITPA, HRAS | TSHR 3855/4885THRB 2741/4885CES2 4043/4885 |
| US-20200247786-A1 | PHARMACEUTICAL COMPOSITION DERIVED FROM TECOMA PLANT AND A METHOD FOR TREATING CANCER | TEC, TMSB10, MALT1 | TSHR 2145/4885THRB 474/4885CES2 4571/4885 |
| US-20190125732-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND A METHOD THEREOF | SYMPK, ITPA, HRAS | TSHR 3855/4885THRB 2741/4885CES2 4043/4885 |
| US-20120189670-A1 | PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS INCLUDING INHIBITORS OF THE PLECKSTRIN HOMOLOGY DOMAIN AND METHODS FOR USING SAME | PLEKHG3, PLEC, PLEKHA1 | TSHR 3939/4885THRB 3404/4885CES2 3486/4885 |
| US-20050014730-A1 | Anti-fungal formulation of triterpene and essential oil | BET1, VRK1, VRK2 | TSHR 3878/4885THRB 2341/4885CES2 4195/4885 |
| US-20060003948-A1 | Compositions that include a triterpene and a carrier | PGGT1B, BET1, CYP51A1 | TSHR 4546/4885THRB 4384/4885CES2 1946/4885 |
| US-11124499-B2 | Pharmaceutical composition derived from Tecoma plant and a method for treating cancer | TEC, TMSB10, MALT1 | TSHR 2145/4885THRB 474/4885CES2 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.